Literature DB >> 10673467

Mechanisms in COPD: differences from asthma.

P J Barnes1.   

Abstract

Although considerable progress has been made in understanding the cellular and molecular mechanisms of asthma, much less attention has been paid to COPD. The inflammatory process in COPD is very different from that in asthma, with different inflammatory cells, mediators, inflammatory effects, and response to therapy. Airway inflammation in asthma, characterized by an eosinophilic inflammation affecting all the airways but not lung parenchyma, is linked to airway hyperresponsiveness. In COPD, there is a predominantly neutrophilic inflammation in the airways. Parenchymal destruction is an important irreversible feature and leads to airflow obstruction through dynamic compression. The eosinophilic inflammation in asthma is markedly suppressed by corticosteroids, but they have no appreciable effect on the inflammation in COPD, consistent with a failure of long-term corticosteroids to alter the progression of COPD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10673467     DOI: 10.1378/chest.117.2_suppl.10s

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  59 in total

1.  Asthma, chronic obstructive pulmonary disease, and type 2 diabetes in the Women's Health Study.

Authors:  Yiqing Song; Anna Klevak; Joann E Manson; Julie E Buring; Simin Liu
Journal:  Diabetes Res Clin Pract       Date:  2010-10-06       Impact factor: 5.602

2.  Irreversible airway obstruction in asthma.

Authors:  Louis-Philippe Boulet
Journal:  Curr Allergy Asthma Rep       Date:  2009-03       Impact factor: 4.806

Review 3.  Overcoming gaps in the management of asthma in older patients: new insights.

Authors:  Pranoy Barua; M Sinead O'Mahony
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

4.  Chronic obstructive pulmonary disease: an overview.

Authors:  John F Devine
Journal:  Am Health Drug Benefits       Date:  2008-09

Review 5.  Acute lung failure.

Authors:  Rob Mac Sweeney; Daniel F McAuley; Michael A Matthay
Journal:  Semin Respir Crit Care Med       Date:  2011-10-11       Impact factor: 3.119

Review 6.  An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease.

Authors:  Sonal Singh; Yoon K Loke
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

7.  Misdiagnosis of patients receiving inhaled therapies in primary care.

Authors:  José Luis Izquierdo; Antonio Martín; Pilar de Lucas; José Miguel Rodríguez-González-Moro; Carlos Almonacid; Alexandra Paravisini
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

8.  CCL18 production is decreased in alveolar macrophages from cigarette smokers.

Authors:  Florian Kollert; Corina Probst; Joachim Müller-Quernheim; Gernot Zissel; Antje Prasse
Journal:  Inflammation       Date:  2009-06       Impact factor: 4.092

Review 9.  Inhaled corticosteroids in the long-term management of patients with chronic obstructive pulmonary disease.

Authors:  Don D Sin; S F Paul Man
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Association of ADAM33 gene polymorphisms with COPD in a northeastern Chinese population.

Authors:  Xinyan Wang; Lei Li; Jinling Xiao; Chengzhen Jin; Kun Huang; Xiaowen Kang; Xiaomei Wu; Fuzhen Lv
Journal:  BMC Med Genet       Date:  2009-12-10       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.